Treatment for Melanoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Melanoma+4 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study staff attitudes towards a new practice of inserting IVs on the same side as lymph node removal.

Eligible Conditions
  • Melanoma
  • Thoracic Cancers
  • Breast Cancer
  • Lymphedema

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Through study completion, an average of 2 years.

Baseline
Study participation acceptance
Month 12
Volumetric measurements
Month 12
Lymphedema symptoms; patient reported outcomes (PRO)
Lymphedema
Year 2
Identify facilitators and barriers that impact staff uptake for implementation of practice change involving ipsilateral IV insertion in patients with axillary lymphadenectomy/dissection.

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

50 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 2 years.

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,159 Previous Clinical Trials
3,188,528 Total Patients Enrolled
16 Trials studying Melanoma
401 Patients Enrolled for Melanoma
Deborah H Allen, PhDPrincipal InvestigatorDuke Health

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Participants who have a history of bilateral or unilateral SLNP, or a previous or current failed contralateral IV attempt, may proceed to IV placement in the ipsilateral arm on the first attempt.
Adults 18 years of age or older are allowed to vote in this election.
forms The participants in the study read, reviewed, and signed a form that specified that they agreed to take part in the study.
agent This text is saying that someone is scheduled to have a scan that involves a contrast agent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: November 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.